VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2017 | Is the current dose of pembrolizumab approved for treating lung cancer too high?

Daniel Goldstein • 2 Jun 2017
ASCO 2017
Warning: array_filter() expects parameter 1 to be array, bool given in /home/customer/www/vjoncology.com/public_html/wp-content/themes/vj/single.php on line 281

Daniel Goldstein, MD, from Davidoff Cancer Center, Petah Tikva, Israel, talks to us about the possibility of lowering the current FDA-approved dose of pembrolizumab for the treatment of PD-L1-positive lung cancer and notes that studies have shown equivalent efficacies of the drug in two different doses. He states that lowering the prescription dose from 200mg, the FDA-approved dose, to 150mg, may save $0.8 billion annually, whilst maintaining the same level of efficacy in patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter